Bipolar disorder and gastric sleeve surgery present a complex clinical intersection that requires careful, coordinated management. Sleeve gastrectomy is one of the most commonly performed bariatric procedures in the UK, yet for people living with bipolar disorder, the physiological and psychological changes it triggers — including hormonal shifts, altered medication absorption, and rapid weight loss — can have significant implications for mood stability. Understanding the risks, preparing thoroughly with an NHS multidisciplinary team, and ensuring robust psychiatric support before and after surgery are essential steps for anyone with bipolar disorder considering this procedure.

How Gastric Sleeve Surgery Affects Bipolar Disorder

Gastric sleeve surgery can influence mood regulation through hormonal changes, gut–brain axis disruption, and surgical stress, with some studies reporting increased risk of mood episodes and self-harm in people with pre-existing bipolar disorder.

Gastric sleeve surgery, formally known as sleeve gastrectomy, is one of the most commonly performed bariatric procedures in the UK. It involves removing approximately 75–80% of the stomach, creating a narrow, tube-shaped pouch. For individuals living with bipolar disorder, this significant anatomical change can have meaningful implications for both physical and mental health.

Obesity is disproportionately prevalent among people with bipolar disorder, partly due to the metabolic side effects of mood-stabilising medications and partly due to lifestyle factors associated with the condition. Weight loss surgery can therefore seem an attractive option. However, the physiological and psychological stress of surgery — including hormonal shifts, dietary restriction, and rapid weight loss — may influence mood regulation in ways that are not yet fully understood.

Experiencing these side effects? Our pharmacists can help you navigate them →

Some observational studies and case series suggest that bariatric surgery may be associated with mood episodes in vulnerable individuals, including periods of hypomania, depression, or mixed states. The mechanisms proposed in the literature — such as changes in gut hormones including ghrelin (which is substantially reduced after sleeve gastrectomy), alterations in the gut–brain axis, and disrupted sleep during recovery — remain hypotheses rather than established causal pathways. There is currently no official clinical consensus confirming a direct causal link between gastric sleeve surgery and worsening bipolar disorder, but the potential interaction warrants careful pre- and post-operative monitoring.

Importantly, some studies have also identified an increased risk of self-harm and suicidal ideation following bariatric surgery in people with pre-existing mental health conditions. This does not mean surgery is contraindicated, but it does mean that proactive mental health planning and safeguarding should form part of the care pathway. Anyone experiencing thoughts of self-harm or suicide should contact their GP for a same-day appointment, call NHS 111, attend their nearest A&E, or contact the Samaritans on 116 123 (free, 24 hours).

For patients with well-controlled bipolar disorder who are considering bariatric surgery, the benefits of significant weight loss — including reduced cardiovascular risk and improved metabolic health — may outweigh the risks, provided that an individualised risk–benefit assessment is conducted within a multidisciplinary team (MDT) and that appropriate psychiatric support is in place throughout the process.

Medication Absorption Changes After Bariatric Surgery

Sleeve gastrectomy accelerates gastric emptying and reduces stomach acid, which can alter the bioavailability of mood stabilisers; lithium toxicity risk rises with post-operative dehydration, and modified-release formulations may need switching to immediate-release versions.

One of the most clinically significant concerns for people with bipolar disorder undergoing gastric sleeve surgery is the potential for altered medication absorption. Sleeve gastrectomy reduces stomach volume and accelerates gastric emptying, which can change how oral medications are absorbed into the bloodstream.

Unlike gastric bypass procedures, sleeve gastrectomy does not bypass the small intestine, meaning the primary site of drug absorption remains intact. However, reduced stomach acid production and faster gastric transit can still affect the bioavailability of certain mood-stabilising drugs. Key medications to consider include:

• Lithium — The most important post-operative risk with lithium relates to dehydration and altered renal handling rather than gastric absorption alone. Lithium is excreted almost entirely by the kidneys, and dehydration — common in the early post-operative period — can cause serum lithium levels to rise rapidly, potentially to toxic levels. Lithium has a narrow therapeutic index, meaning even small fluctuations in blood levels can result in toxicity or loss of efficacy. Concurrent use of NSAIDs or ACE inhibitors can further raise lithium levels and should be reviewed. Patients should follow sick-day rules: if they are unable to maintain adequate fluid intake due to vomiting, diarrhoea, or illness, they should seek prompt medical advice and their prescriber may advise temporarily withholding lithium pending a level check.

• Sodium valproate — Extended-release (modified-release) formulations may not dissolve and absorb correctly following anatomical changes to the stomach. Switching to an immediate-release formulation under specialist guidance may be necessary. For anyone taking valproate who could become pregnant, the MHRA Valproate Pregnancy Prevention Programme (PPP) requirements apply regardless of surgery; patients should discuss contraception and pregnancy planning with their prescriber.

• Lamotrigine — Evidence on absorption after bariatric surgery is limited and variable; clinical monitoring remains advisable rather than assuming stability.

• Quetiapine and other atypical antipsychotics — Absorption profiles may shift post-operatively, potentially requiring dose review.

Where possible, immediate-release formulations should be preferred over modified-release or enteric-coated preparations in the post-operative period, as these are less likely to be affected by altered gastric transit. Liquid or orodispersible formulations are available for some agents and may be particularly useful during the early recovery phase when patients are on a liquid or pureed diet. A clinical pharmacist with experience in bariatric medicine should be involved in medication review; the UK Specialist Pharmacy Service (SPS) and BOMSS publish practical guidance on medicines management after bariatric surgery.

Patients should be advised never to crush or split modified-release tablets without explicit guidance from their prescriber or pharmacist, as this can lead to dose dumping or reduced efficacy.

Therapeutic drug monitoring (TDM) is standard UK practice for lithium and should be performed more frequently around the time of surgery and in the first several months post-operatively. TDM for sodium valproate may be indicated in certain clinical circumstances; for lamotrigine and atypical antipsychotics, clinical monitoring and symptom review are the primary tools rather than routine serum levels. Any unexplained changes in mood, cognition, or physical symptoms such as tremor or nausea should prompt an urgent review.

If you suspect a side effect from any medication, you can report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Psychiatric Assessment and NICE Guidance Before Surgery

NICE guidance requires a multidisciplinary assessment before bariatric surgery; for people with bipolar disorder, psychiatric evaluation is best practice, and most NHS centres require evidence of mental health stability before proceeding.

In the UK, access to bariatric surgery through the NHS is governed primarily by NICE guidance. NICE CG189 (Obesity: identification, assessment and management) sets out eligibility criteria, recommending surgery for adults with a BMI of 40 or above, or a BMI of 35–39.9 with a significant obesity-related comorbidity. NICE NG28 (Type 2 diabetes in adults: management) additionally supports consideration of metabolic surgery for adults with type 2 diabetes at a BMI of 30–34.9 where blood glucose is inadequately controlled, and at lower BMI thresholds for people of South Asian or other high-risk ethnic backgrounds. Local commissioning policies may vary.

NICE guidance stipulates that patients must undergo a comprehensive multidisciplinary assessment (MDA) before surgery is approved. This MDA includes psychological or psychiatric input as clinically indicated by the team, rather than a mandatory formal psychiatric assessment for every patient. For individuals with bipolar disorder, however, psychiatric evaluation will almost always be appropriate and is considered best practice.

The pre-operative psychiatric assessment typically aims to:

• Establish the current stability of the patient's mental health

• Review the adequacy and consistency of psychiatric follow-up

• Identify any history of impulsivity, substance misuse, or disordered eating that may complicate post-operative outcomes

• Assess the patient's understanding of the psychological demands of bariatric surgery

• Ensure that realistic expectations are in place regarding mood and quality of life after surgery

NICE guidance does not categorically exclude people with bipolar disorder from bariatric surgery, but it does emphasise that active, unstable psychiatric illness should be addressed before surgery proceeds. Most NHS bariatric centres will require evidence of psychiatric stability before proceeding; the precise definition of stability and the timeframe required vary between centres and are determined by local policy rather than a fixed national standard.

Patients are encouraged to be fully transparent with their surgical team about their diagnosis, current medications, and psychiatric history. Concealing a mental health diagnosis may compromise safety and post-operative care planning. A collaborative approach between the bariatric team, psychiatrist, and GP is considered best practice and is strongly aligned with NHS integrated care principles.

Managing Mood Stabilisers Following Gastric Sleeve

Post-operative management of mood stabilisers requires close monitoring, particularly for lithium due to dehydration risk; liquid or immediate-release formulations may be needed, and therapeutic drug monitoring should be increased in the first three to six months.

The post-operative period following gastric sleeve surgery requires particularly vigilant management of mood-stabilising medications. In the immediate weeks after surgery, patients are restricted to a liquid or pureed diet, which can complicate the administration of standard oral formulations. This phase demands close liaison between the bariatric team and the prescribing psychiatrist or GP.

Lithium requires especially careful management. Given its narrow therapeutic index and almost exclusive renal excretion, post-operative changes in fluid intake, dietary sodium, and renal function can rapidly shift serum lithium levels. Dehydration — a common risk in the early post-operative period due to reduced oral intake and the risk of vomiting — can cause lithium levels to rise dangerously. Patients should maintain consistent fluid and salt intake and follow sick-day rules: if they develop vomiting, diarrhoea, or are otherwise unable to maintain adequate hydration, they should seek prompt medical advice and their prescriber may advise withholding the next dose pending an urgent level check. Renal function (U&Es) should be monitored alongside lithium levels, particularly in the post-operative period. Concurrent use of NSAIDs (including ibuprofen) or ACE inhibitors can significantly raise lithium levels and should be avoided unless specifically reviewed by a prescriber.

Patients and carers should be aware of the signs of lithium toxicity, which include:

• Coarse tremor

• Confusion or drowsiness

• Nausea, vomiting, or diarrhoea

• Muscle twitching or incoordination

If any of these symptoms occur, patients should seek same-day urgent medical assessment via their GP, NHS 111, or A&E. The next dose of lithium should be withheld pending review. Serum lithium levels should be checked more frequently in the first three to six months post-surgery — and whenever there is a clinical change — with adjustments made as indicated. When stable, lithium levels should be checked at least every three months in line with BNF and NICE CKS recommendations.

For patients on sodium valproate, switching from modified-release to immediate-release formulations may be necessary post-operatively, under specialist guidance. Anyone taking valproate who could become pregnant must be enrolled in the MHRA Valproate Pregnancy Prevention Programme (PPP); this requirement is unaffected by surgery and should be discussed with the prescriber. Liquid formulations of several mood stabilisers are available and may be preferable during the early recovery phase.

Lamotrigine and some atypical antipsychotics may be better tolerated post-operatively, though dose reviews and clinical monitoring remain important. A clinical pharmacist should be involved in reviewing all formulations before and after surgery, with reference to SPS and BOMSS guidance.

Long-term, patients should not assume that their pre-operative medication regimen will remain appropriate. Regular medication reviews with a psychiatrist, combined with lithium TDM at the frequency recommended by the BNF and NICE CKS, form the cornerstone of safe long-term management.

Risks and Considerations for People With Bipolar Disorder

Key risks include perioperative mood episodes, increased suicidality, faster alcohol absorption leading to higher intoxication risk, disordered eating, and nutritional deficiencies — particularly thiamine, B12, and folate — which can affect mood and neurological function.

Beyond medication management, there are broader psychological and clinical risks that people with bipolar disorder should carefully consider before proceeding with gastric sleeve surgery. Understanding these risks does not mean surgery is contraindicated, but it does mean that informed decision-making and robust support structures are essential.

Mood episode risk: The perioperative period — encompassing the weeks before and after surgery — is a time of significant physical and emotional stress. Disrupted sleep, pain, dietary restriction, and altered body image can all act as triggers for mood episodes in susceptible individuals. Both depressive and hypomanic or manic episodes have been reported in the bariatric literature following surgery.

Self-harm and suicidality: Some studies have identified an increased risk of self-harm and suicidal ideation following bariatric surgery, particularly in people with pre-existing mental health conditions. Patients, carers, and clinicians should be alert to early warning signs. Anyone experiencing thoughts of self-harm or suicide should contact their GP for a same-day appointment, call NHS 111, attend A&E, or contact the Samaritans on 116 123 (free, 24 hours).

Alcohol and substance use: Research consistently shows an increased risk of alcohol use disorder following bariatric surgery. This is partly explained by altered alcohol pharmacokinetics: after sleeve gastrectomy, alcohol is absorbed more rapidly, leading to faster and higher peak blood alcohol concentrations than before surgery. For individuals with bipolar disorder, who may already have an elevated vulnerability to substance misuse, this risk deserves particular attention. Most bariatric programmes advise abstinence from alcohol for at least the first six to twelve months post-operatively; patients should follow their local programme's guidance and discuss any concerns with their clinical team.

Body image and eating behaviours: Rapid and significant weight loss can provoke complex psychological responses. Disordered eating patterns, including restriction, bingeing, or grazing, are not uncommon post-operatively and may interact with mood instability.

Nutritional deficiencies: Deficiencies in B vitamins (particularly B12, folate, and thiamine), vitamin D, and iron are common after sleeve gastrectomy. Folate and B12 have established associations with mood regulation and neurological function, making supplementation and monitoring especially relevant for this patient group. Thiamine (vitamin B1) deficiency is a particular concern if patients experience prolonged vomiting post-operatively. Symptoms of thiamine deficiency — including confusion, visual disturbance, and difficulty with balance or coordination — require urgent medical assessment, as Wernicke's encephalopathy is a serious and potentially irreversible complication. If thiamine deficiency is suspected, parenteral thiamine should be given urgently; oral supplementation is not adequate in this situation. BOMSS guidance sets out recommended post-operative supplementation and biochemical monitoring schedules.

Patients should be encouraged to discuss all of these considerations openly with their clinical team before making a final decision about surgery.

Working With Your NHS Team for Safe Long-Term Care

Safe long-term care requires integrated communication between the GP, psychiatrist, bariatric team, dietitian, and pharmacist, with enhanced psychiatric follow-up, regular blood monitoring, lifelong supplementation, and a clear crisis plan in place.

Achieving safe, long-term outcomes after gastric sleeve surgery with a diagnosis of bipolar disorder requires a genuinely integrated approach across multiple NHS services. No single clinician can manage all aspects of care in isolation, and patients benefit most when their GP, psychiatrist, bariatric team, dietitian, and clinical pharmacist communicate effectively and regularly.

Before surgery, patients should ensure that:

• Their GP is fully informed of the planned procedure and is coordinating shared care

• Their psychiatrist or community mental health team (CMHT) has been consulted and has provided a formal opinion on psychiatric fitness for surgery

• A post-operative monitoring plan for mood and medications has been agreed in advance, and shared in writing across all relevant teams

Following surgery, regular follow-up appointments are essential. BOMSS recommends a minimum of two years of specialist bariatric follow-up after surgery, after which ongoing monitoring should continue in primary care with access to specialist services as needed; local pathways vary. Patients with bipolar disorder should advocate for enhanced psychiatric follow-up during this period, particularly in the first year when the risk of mood destabilisation may be highest.

Typical annual blood tests after sleeve gastrectomy include full blood count (FBC), urea and electrolytes (U&Es), liver function tests (LFTs), ferritin, folate, vitamin B12, vitamin D, and calcium (with parathyroid hormone if indicated). Lithium levels and renal function should be monitored at the frequency recommended by the BNF and NICE CKS. Lifelong vitamin and mineral supplementation is required after sleeve gastrectomy; the specific regimen should be agreed with the bariatric dietitian in line with BOMSS guidance.

Patients are also encouraged to:

• Keep a mood diary to help identify early warning signs of relapse

• Maintain open communication with their care team about any changes in mood, sleep, appetite, or medication tolerance

• Contact their GP or mental health team promptly if they experience a significant mood change, signs of lithium toxicity, or concerns about their medication

• Report any suspected medication side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app

In a mental health crisis, patients should contact their GP for a same-day appointment, call NHS 111, attend A&E, or call the Samaritans on 116 123 (free, 24 hours).

With careful planning, transparent communication, and a well-coordinated NHS team, many people with bipolar disorder can safely undergo gastric sleeve surgery and achieve meaningful improvements in their physical health and overall quality of life.

Frequently Asked Questions